- Intravenous Infusions Swings From GH¢165,458 Loss to Profit as Turnaround Takes Hold
Intravenous Infusions PLC has returned to profitability in the first half of 2026, swinging from a pre-tax loss of GH¢165,458 a year earlier to a profit of GH¢36,824, as aggressive cost restructuring and a shift towards higher-margin products outweighed a sharp decline in revenue.
The Koforidua-based pharmaceutical manufacturer said revenue for the six months ended June 30, 2026 fell 39.00% year-on-year to GH¢4.28 million, reflecting a deliberate decision to move away from price-sensitive tenders and distribution lines that generated volume but consumed working capital without producing adequate returns.
The strategy meant the company sold less but extracted significantly more value from the business it retained.
Gross profit increased 44.00% to GH¢3.11 million, from GH¢2.17 million in the corresponding period of 2025, demonstrating a significant improvement in the quality of revenue and underlying margins even as headline sales contracted.
The sharp divergence between falling revenue and rising gross profit is arguably the clearest evidence of the company’s turnaround strategy.
Rather than pursuing sales growth at almost any cost, management has begun prioritising products and commercial channels capable of generating stronger margins and cash returns. That approach is particularly significant for a manufacturing company where working capital can become heavily tied up in inventories, receivables and low-margin institutional contracts.
Intravenous Infusions said operating and other expenses also declined 40% year-on-year, following cost restructuring, efficiency initiatives and tighter controls over overhead expenditure.
Those savings, combined with the stronger gross profit performance, lifted profit before finance costs and tax to approximately GH¢285,507 from just GH¢9,699 in the first half of 2025.
That represents an increase of about 2,843.18%, illustrating the scale of the operational improvement achieved even before financing costs and taxes are taken into account.
After finance costs, the company moved from a pre-tax loss of GH¢165,458 in H1 2025 to a pre-tax profit of GH¢36,824 this year.
The swing represents a GH¢202,282 improvement in the bottom line.
For investors, however, the more important issue is whether the return to profitability can be sustained rather than the absolute size of the first-half profit.
Management itself appears conscious of that distinction, describing the performance as the beginning of a turnaround rather than the completion of one.
The company said it successfully raised primary capital during the period through a convertible loan, increasing stated capital by 41%. Management described the transaction as a fundamental turning point that strengthened the company’s capital base and created a platform from which to restore profitable long-term growth.
The capital injection is particularly important because Intravenous Infusions’ restructuring strategy requires more than accounting profitability.
Manufacturers need sufficient liquidity to purchase raw materials, maintain equipment, finance production cycles and extend appropriate credit to customers. A stronger capital base can therefore give management greater flexibility to pursue profitable orders without returning to the working-capital pressures associated with low-return business.
Intravenous Infusions manufactures pharmaceutical products and has operated from Koforidua since 1969. Its performance has therefore attracted attention not only from shareholders but also from a broader policy perspective as Ghana seeks to strengthen domestic pharmaceutical manufacturing and reduce dependence on imported medical products.
The company’s turnaround could become more strategically important if management can translate improved margins into sustained production growth.
During the second half of 2026, Intravenous Infusions plans to concentrate on three strategic pillars: portfolio optimisation, cost and operational efficiency, and commercial momentum.
Portfolio optimisation is likely to remain central to the strategy. The first-half numbers demonstrate that revenue growth alone does not necessarily translate into shareholder value when sales are concentrated in low-margin contracts requiring significant amounts of working capital.
By exiting some price-sensitive tenders and distribution arrangements, the company effectively accepted lower turnover in exchange for substantially stronger gross profitability.
That trade-off appears to have worked during the first six months.
A 39% contraction in revenue is substantial, and there is a limit to how long earnings can expand primarily through cost reductions and portfolio rationalisation. Once the major restructuring benefits have been captured, sustainable profit growth will increasingly require the company to rebuild revenue from products and markets capable of generating acceptable margins.
Management acknowledged that significant execution work remains.
On page two of its statement, the board said the return to profitability, substantial improvement in gross profit and strengthening of the capital base represented a strong beginning to the turnaround. It said management would now focus on scaling profitable revenue, improving cash generation and delivering sustainable long-term value to shareholders.
The first-half performance therefore represents a notable financial reset for Intravenous Infusions.
The company has moved from losses into profit, expanded gross earnings despite sharply lower sales, cut operating costs and strengthened its capital base.
The next stage will be harder: turning the improved cost structure into sustained top-line growth without sacrificing the margin discipline that restored profitability.
For shareholders, that will determine whether H1 2026 marks merely a temporary improvement or the beginning of a durable recovery for one of Ghana’s longstanding pharmaceutical manufacturers.
